CD33


Also found in: Wikipedia.

CD33

a type I transmembrane protein present on myeloid cells and myeloid precursors; expressed in many acute nonlymphoblastic leukemias and some B-cell chronic lymphocytic leukemias.
Mentioned in ?
References in periodicals archive ?
An argument might be made for considering case 2 a form of primitive acute myeloid leukemia, because this neoplasm weakly expressed CD33 and CD4.
Cytochemistry Immunophenotype (-) Sudan black B (+) Platelet glycoprotein Ib (CD42b) (-) Myeloperoxidase (+) Platelet glycoprotein IIb/ IIIa (CD41) (-) Terminal (+) Platelet glycoprotein IIIa deoxynucleotidyltransferase (CD61) (+) Periodic acid-Schiff, (+) Factor VIII-related antigen acid phosphatase (+/-) Nonspecific esterase (+/-) HLA-DR, CD33, CD34 (focal, paranuclear)
These antibodies included CD10, HLA-DR (Ia), CD11b, CD15, CD13, CD33, CD14, and CD45.
as a single agent for patients with CD33 positive AML in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy.
Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development.
SGN-33, or lintuzumab, is a humanized monoclonal antibody that targets the CD33 antigen that is currently in a phase I clinical trial for the treatment of AML and myelodysplastic syndromes (MDS).
Flow cytometry on peripheral blood at the time of relapse showed blasts expressing CD34, CD56, CD33, and cytoplasmic CD3.
6,17] Double-labeling experiments with anti-E-cadherin antibody revealed coexpression with the molecules glycophorin A and the transferrin receptor, while no coexpression was found with lymphoid (CD2, CD3, CD10, CD19, CD56, and CD62L) and myeloid (CD13, CD33, and CD41) markers.
SGN-33, or lintuzumab, is a humanized monoclonal antibody that targets the CD33 antigen, which is expressed on a number of hematologic malignancies, including AML, MDS and several myeloproliferative disorders.
The following monoclonal antibodies were used: CD3, CD4, CD5, CD7, CD8, CD10, CD13, CD14, CD19, CD22, CD33, CD34, CD45, anti-[Kappa], anti-[Lambda], HLA-DR (Becton Dickinson), terminal deoxynucleotidyl transferase (Dako), and intracytoplasmic CD3 and myeloperoxidase (Caltag, Burlingame, Calif).
Immunophenotyping analysis confirmed the myeloid lineage assignment by positive expression of CD13, CD33, and CD117.
Abstract #: 14 First author: Michael Aigner, PhD, University Hospital of Erlangen, Erlangen, Germany Oral presentation: Sunday, December 5, 4:45 PM Location: Room 311 ABCD Investigators will report for the first time on the activity of the Company's CD33 BiTE antibody against human cancer cell lines.